PMID- 25373322
OWN - NLM
STAT- MEDLINE
DCOM- 20151026
LR  - 20211021
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 31
IP  - 12
DP  - 2014 Dec
TI  - Clinical value of serum HMGB1 in diagnosis and prognosis of laryngeal squamous 
      cell carcinoma.
PG  - 316
LID - 10.1007/s12032-014-0316-x [doi]
AB  - Laryngeal squamous cell carcinoma (LSCC) is one of the most common malignancies 
      in the head and neck region. Recently, aberrantly expressed high-mobility group 
      box 1 (HMGB1) has received a great deal of attention as a potential biomarker for 
      cancer diagnosis and prognosis. Therefore, the aim of this study was to estimate 
      HMGB1 levels in serum in LSCC patients and healthy controls and evaluated the 
      potential of serum HMGB1 as a noninvasive biomarker for diagnosis and prognosis 
      in LSCC. Serum HMGB1 levels were analyzed in 71 LSCC patients and 50 healthy 
      controls. The serum HMGB1 level was significantly higher in LSCC patients 
      compared with the healthy controls (4.81 +/- 2.33 vs. 3.21 +/- 1.08 ng/mL, P < 
      0.001). High serum HMGB1 was significantly associated with T classification (P = 
      0.005), N classification (P = 0.002), and clinical stage (P = 0.001). The area 
      under ROC curve was 0.716, and the sensitivity and specificity were 42.3 and 
      92.0%, respectively. The Kaplan-Meier plots showed that patients with high serum 
      HMGB1 had a poorer overall survival than those with low serum HMGB1 (P = 0.036). 
      Serum HMGB1 levels are significantly associated with the progression of LSCC. In 
      this population, HMGB1 has a poor sensitivity, but a high specificity for the 
      diagnosis of LSCC. Serum HMGB1 level has potential as a biomarker for the 
      prognosis in LSCC patients.
FAU - Qiu, Guangbin
AU  - Qiu G
AD  - Department of Laboratory Medicine, No. 202 Hospital of PLA, Guangrong Street, No. 
      5, Shenyang, 110003, China.
FAU - Li, Yunhui
AU  - Li Y
FAU - Liu, Zheng
AU  - Liu Z
FAU - Wang, Mengran
AU  - Wang M
FAU - Ge, Jingjing
AU  - Ge J
FAU - Bai, Xiaozhong
AU  - Bai X
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141106
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HMGB1 Protein)
RN  - 0 (HMGB1 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/blood
MH  - Carcinoma, Squamous Cell/*blood/*diagnosis/mortality/pathology
MH  - Case-Control Studies
MH  - Enzyme-Linked Immunosorbent Assay/methods
MH  - Female
MH  - HMGB1 Protein/*blood
MH  - Head and Neck Neoplasms/*blood/*diagnosis/mortality/pathology
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/*blood/*diagnosis/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - ROC Curve
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - Survival Analysis
EDAT- 2014/11/07 06:00
MHDA- 2015/10/27 06:00
CRDT- 2014/11/07 06:00
PHST- 2014/10/14 00:00 [received]
PHST- 2014/10/30 00:00 [accepted]
PHST- 2014/11/07 06:00 [entrez]
PHST- 2014/11/07 06:00 [pubmed]
PHST- 2015/10/27 06:00 [medline]
AID - 10.1007/s12032-014-0316-x [doi]
PST - ppublish
SO  - Med Oncol. 2014 Dec;31(12):316. doi: 10.1007/s12032-014-0316-x. Epub 2014 Nov 6.